New Delhi, Sept. 22 -- The Central Drugs Standard Control Organisation (CDSCO) has identified 220 drug samples as Not of Standard Quality (NSQ) during routine regulatory surveillance in August 2026, including 29 samples identified by Central Drugs Laboratories and 191 by State Drugs Testing Laboratories.

According to the monthly NSQ and Spurious Drug Alert issued by CDSCO, one drug sample from the National Capital Territory (NCT) of Delhi was also identified as a spurious drug.

The spurious drug was allegedly manufactured by unauthorised manufacturers using a brand name owned by another company. The matter is currently under investigation, and action will be taken as per the Drugs and Cosmetics Act and Rules, according to the regulatory...